LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

16.89 -4.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.89

Max

17.65

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

61.417

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+39.74% upside

Dividenden

By Dow Jones

Volgende Winsten

29 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-88M

912M

Vorige openingsprijs

21.79

Vorige sluitingsprijs

16.89

Nieuwssentiment

By Acuity

44%

56%

136 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2026, 20:38 UTC

Winsten

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mrt 2026, 23:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

10 mrt 2026, 23:57 UTC

Marktinformatie

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mrt 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mrt 2026, 23:35 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mrt 2026, 23:06 UTC

Winsten

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mrt 2026, 22:51 UTC

Belangrijke Nieuwsgebeurtenissen

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mrt 2026, 21:21 UTC

Winsten

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mrt 2026, 21:15 UTC

Winsten

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mrt 2026, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mrt 2026, 21:14 UTC

Winsten

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mrt 2026, 21:13 UTC

Winsten

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mrt 2026, 21:12 UTC

Winsten

Franco-Nevada 4Q Rev $597.3M >FNV

10 mrt 2026, 21:12 UTC

Winsten

Franco-Nevada 4Q EPS $1.90

10 mrt 2026, 20:57 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

10 mrt 2026, 20:44 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:34 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

10 mrt 2026, 20:34 UTC

Marktinformatie
Winsten

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mrt 2026, 20:23 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:16 UTC

Winsten

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mrt 2026, 20:14 UTC

Winsten

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mrt 2026, 20:14 UTC

Winsten

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mrt 2026, 20:13 UTC

Winsten

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mrt 2026, 20:12 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

39.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  39.74%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

136 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat